ZVRA
Zevra Therapeutics, Inc.
Biotechnology · Healthcare · United States
11.18
close · 2026-08-13
value
82
cheaper than peers82
quality
98
stronger fundamentals98
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 10.65× | 79 |
| price to sales | 5.01× | 79 |
| price to book | 3.21× | 71 |
| EV to EBITDA | 11.50× | 70 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 42.3% | 95 |
| debt to equity | 0.7% | 95 |
| return on equity | 34.8% | 87 |
| revenue growth | 53.3% | 61 |
4 of 4 measures available
Facts
| market cap | $664M |
| free cash flow | $48.4M |
| employees | 61 |
| first trade | 2015-04-16 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-10 |